Angiotensin III (human, mouse): RAAS Peptide for Cardiovascular and Neuroendocrine Research

Executive Summary: Angiotensin III (human, mouse) is a hexapeptide (Arg-Val-Tyr-Ile-His-Pro-Phe) generated by N-terminal cleavage of angiotensin II in the renin-angiotensin-aldosterone system (RAAS) (Oliveira et al., 2025). It mediates approximately 40% of the vasopressor activity of angiotensin II and fully stimulates aldosterone secretion (see atomic insights). Angiotensin III binds AT1 and AT2 receptor subtypes, exhibiting relative specificity for AT2. Experimental use in rodents shows it elicits both blood pressure and dipsogenic responses, paralleling angiotensin II. The peptide’s well-characterized physicochemical profile, including a molecular weight of 931.09 and high solubility in water, ethanol, and DMSO, supports its reproducibility in laboratory workflows (APExBIO technical data).

Biological Rationale

Angiotensin III (human, mouse) is a core effector peptide in the RAAS pathway. It is produced in vivo by aminopeptidase-mediated N-terminal truncation of angiotensin II (Oliveira et al., 2025). The RAAS regulates blood pressure, electrolyte balance, and fluid homeostasis. Angiotensin III accounts for a significant proportion of RAAS-mediated pressor responses and is essential for full aldosterone secretion, functions traditionally attributed to angiotensin II (see core RAAS peptide). Its interaction with both AT1 and AT2 receptors distinguishes it from other angiotensin fragments, permitting nuanced experimental interrogation of receptor subtype signaling. The existence of angiotensin III in both human and mouse systems supports translational and comparative research.

Mechanism of Action of Angiotensin III (human, mouse)

Angiotensin III is formed by the enzymatic removal of the N-terminal aspartic acid from angiotensin II, yielding the sequence Arg-Val-Tyr-Ile-His-Pro-Phe (Oliveira et al., 2025). It is biologically active and binds to both AT1 and AT2 receptors, though it demonstrates higher relative selectivity for AT2. Upon receptor engagement, angiotensin III triggers intracellular signaling cascades that result in vasoconstriction (mediated by AT1) and aldosterone synthesis (mediated by both AT1 and AT2). In addition, angiotensin III suppresses renin release, reinforcing negative feedback in the RAAS system. In rodent brain models, exogenous angiotensin III induces increases in blood pressure and stimulates thirst, which provides a robust readout for neuroendocrine and cardiovascular research (see translational innovation).

Evidence & Benchmarks

• Angiotensin III mediates ~40% of the vasopressor response attributed to angiotensin II in in vivo rodent models (Oliveira et al., 2025).
• It fully retains aldosterone-inducing capability, equaling angiotensin II in aldosterone secretion assays (Atomic Insights).
• Angiotensin III interacts with AT1 and AT2 receptor subtypes, with experimental evidence for relative AT2 specificity (Oliveira et al., 2025).
• Exogenous administration in rodent brain models elicits both pressor (blood pressure increase) and dipsogenic (thirst-stimulating) responses, paralleling angiotensin II effects (Translational Innovation).
• The peptide’s molecular formula is C46H66N12O9, and it has a molecular weight of 931.09 Da; it is highly soluble: ≥23.2 mg/mL in water, ≥43.8 mg/mL in ethanol, and ≥93.1 mg/mL in DMSO at 20°C (APExBIO datasheet).
• Stable storage is achieved by desiccation at -20°C; prolonged storage in solution is not recommended (APExBIO technical note).

Applications, Limits & Misconceptions

Angiotensin III (human, mouse) is widely used in studies of hypertension, cardiovascular disease modeling, and neuroendocrine signaling. Its robust, reproducible effects on blood pressure and aldosterone output make it suitable for both in vitro and in vivo research. Unlike angiotensin II, angiotensin III offers unique value in dissecting AT2 receptor pathways. The peptide is also applied as a reference standard for receptor binding assays and cell-based functional screens (see cell-based assay optimization)—in contrast to previous reviews, this article provides updated, quantitative storage and solubility parameters, and clarifies the receptor specificity profile.

Common Pitfalls or Misconceptions

• Angiotensin III does not replace angiotensin II in all RAAS-related experiments; their receptor affinities and downstream effects differ.
• The peptide is not a direct substrate for ACE or renin; its generation requires aminopeptidase activity.
• Storage in aqueous solution at ambient temperature leads to degradation—always store desiccated at -20°C.
• Angiotensin III is not effective for experiments requiring C-terminal extensions (e.g., angiotensin I or IV activities).
• It should not be used as a surrogate for AT1-selective responses; AT2 involvement is significant.

Workflow Integration & Parameters

Angiotensin III (human, mouse) (SKU: A1043) is supplied by APExBIO as a solid for reconstitution. For in vitro use, dissolve to ≥23.2 mg/mL in water, ≥43.8 mg/mL in ethanol, or ≥93.1 mg/mL in DMSO at room temperature (20°C). For receptor binding or functional cell assays, prepare fresh aliquots and avoid repeated freeze-thaw cycles. For in vivo rodent studies, dilute immediately prior to injection and monitor pH and osmolarity for physiological compatibility. Long-term storage in solution is not advised; maintain desiccated at -20°C for batch integrity. This article extends previous workflow guides by providing experimentally validated solubility thresholds and explicit storage recommendations.

Conclusion & Outlook

Angiotensin III (human, mouse) is an indispensable tool for RAAS research, enabling targeted interrogation of AT1 and AT2 receptor pathways in cardiovascular and neuroendocrine models. Its defined physicochemical and biological properties underpin reproducibility and translational relevance. As evidence accumulates on the role of angiotensin peptides in viral pathogenesis and advanced disease modeling (Oliveira et al., 2025), Angiotensin III stands as a reference standard. For technical specifications and ordering, see the APExBIO product page. For a future-oriented roadmap integrating current evidence, see this translational innovation article.